Trials / Recruiting
RecruitingNCT03415828
Ethanol Gel Versus Steroid in Refractory Lumbar Discogenic Pain
Intradiscal Gelified Ethanol Versus Intradiscal Steroid in Refractory Lumbar Discogenic Pain: a Randomized Single-blind Study
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 230 (estimated)
- Sponsor
- Gelscom SAS · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
DISCOGEL® is on the market since 2007. About 20,000 kits were sold to date (October 2017). The device re-obtained its CE mark in 2017. A clinical evaluation was performed by bibliographic route in 2016. Clinical data on more than 600 patients treated by DISCOGEL® were analyzed. These data should be confirmed by monitoring on the long term, with a large cohort of patients, over a two-year follow-up period. As part of the post-CE surveillance, the manufacturer GELSCOM is responsible of this "Post-Market Clinical Follow-up" (PMCF) study in accordance with Directive 93/42/EEC and MEDDEV guide 2.12/2, to assess the efficacy and the long-term safety of DISCOGEL®. The study is comparative. The results will evaluate the performance and safety of the CE-marked medical device used in "real life", in comparison with a steroid infiltration, used according to its indication and to the current standards. It will include economic data. Patients and evaluators will be blinded. Both DISCOGEL® and HYDROCORTANCYL 2,5 POUR CENT are authorized products used according to their intended use. This is an interventional, prospective, national, multi-center, comparative, randomized, single-blind (patient and evaluator) post-market clinical study. The primary objective is to compare the short-term efficacy profile of DISCOGEL® versus intradiscal steroid.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Ethanol gel | Intradiscal injection of ethanol gel |
| DRUG | Prednisolone acetate | Intradiscal infiltration of steroids |
Timeline
- Start date
- 2018-05-29
- Primary completion
- 2024-02-29
- Completion
- 2027-05-29
- First posted
- 2018-01-30
- Last updated
- 2025-09-29
Locations
5 sites across 1 country: France
Source: ClinicalTrials.gov record NCT03415828. Inclusion in this directory is not an endorsement.